Premium
Treatment of myelodysplastic syndromes with retinoic acid and 1α‐hydroxy‐vitamin D3 in combination with low‐dose ara‐C is not superior to ara‐C alone. Results from a randomized study
Author(s) -
Hellström Eva,
Robert KarlHenrik,
Samuelsson Jan,
Lindemalm Christina,
Grimfors Gunnar,
Kimby Eva,
Öberg Gunnar,
Winqvist Ingemar,
Billström Rolf,
Carneskog Jan,
Dahlén Magnus,
Stockner Mette,
Wislöff Finn,
Dybedal Ingunn,
Dahl IngerMarie,
Öst Åke
Publication year - 1990
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1990.tb00470.x
Subject(s) - medicine , myelodysplastic syndromes , gastroenterology , retinoic acid , randomized controlled trial , vitamin , complete remission , chemotherapy , oncology , bone marrow , biology , biochemistry , gene
63 evaluable patients with myelodysplastic syndromes (MDS) and 15 with acute myelogenous leukemia (AML) were randomized between low‐dose ara‐C (arm A) and low dose ara‐C in combination with 13‐cis‐retinoic acid (13‐CRA) and 1α‐hydroxy‐vitamin D3 (1α D3) (arm B). 69 patients were evaluable and 18 (26.1%) responded to therapy. The addition of 13‐CRA and 1α D3 had no positive influence on survival of the patients, remission rates or duration of remissions. 12/27 patients in arm A and 6/29 patients in arm B progressed from MDS to AML during the course of the study (p = 0.0527). Arm B gave significantly more side‐effects than arm A (p = 0.005). Therapeutic effects of 13‐CRA and 1α D3 on MDS is not supported by this study. However, an inhibiting effect on AML development in some MDS subgroups cannot be excluded.